A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx®) versus intravenous phenytoin (Dilantin®) in hospital emergency departments
- 31 October 1996
- journal article
- clinical trial
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 18 (5), 953-966
- https://doi.org/10.1016/s0149-2918(96)80051-8
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Intravenous administration of fosphenytoinNeurology, 1996
- Venous Irritation Related to Intravenous Administration of Phenytoin versus FosphenytoinPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1994
- Purple Glove Syndrome: A Complication of Intravenous PhenytoinJournal of Neuroscience Nursing, 1992
- Phenytoin administration by constant intravenous infusion: Selective rates of administrationAnnals of Emergency Medicine, 1991
- Severe soft-tissue injury following intravenous infusion of phenytoin. Patient and drug administration risk factorsArchives of Internal Medicine, 1988
- Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic–Clonic SeizuresNew England Journal of Medicine, 1985
- Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usageJAMA, 1983
- Intravenous phenytoinNeurology, 1978
- Phenytoin Crystallization in Intravenous FluidsDrug Intelligence & Clinical Pharmacy, 1977
- The hemodynamic effects of diphenylhydantoinAmerican Heart Journal, 1967